57 related articles for article (PubMed ID: 12270061)
1. Elevated soluble urokinase plasminogen activator receptor in plasma from patients with idiopathic myelofibrosis or polycythaemia vera.
Jensen MK; Riisbro R; de Nully Brown P; Brünner N; Hasselbalch HC
Eur J Haematol; 2002 Jul; 69(1):43-9. PubMed ID: 12270061
[TBL] [Abstract][Full Text] [Related]
2. Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.
Sloand EM; Pfannes L; Scheinberg P; More K; Wu CO; Horne M; Young NS
Exp Hematol; 2008 Dec; 36(12):1616-24. PubMed ID: 18954937
[TBL] [Abstract][Full Text] [Related]
3. Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study.
Kostopoulou E; Kalavrizioti D; Davoulou P; Sinopidis X; Papachristou E; Goumenos DS; Dimitriou G; Spiliotis BE; Papasotiriou M
Eur J Pediatr; 2024 May; 183(5):2383-2389. PubMed ID: 38448612
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity.
Lundberg LG; Lerner R; Sundelin P; Rogers R; Folkman J; Palmblad J
Am J Pathol; 2000 Jul; 157(1):15-9. PubMed ID: 10880370
[TBL] [Abstract][Full Text] [Related]
5. Circulating miR-10b, soluble urokinase-type plasminogen activator receptor, and plasminogen activator inhibitor-1 as predictors of non-small cell lung cancer progression and treatment response.
Setiawan L; Setiabudy R; Kresno SB; Sutandyo N; Syahruddin E; Jovianti F; Nadliroh S; Mubarika S; Setiabudy R; Siregar NC
Cancer Biomark; 2024; 39(2):137-153. PubMed ID: 38073374
[TBL] [Abstract][Full Text] [Related]
6. Associations between soluble urokinase plasminogen activator receptor (suPAR) concentration and psychiatric disorders - A systematic review and meta-analysis.
Murphy J; Zierotin A; Mongan D; Healy C; Susai SR; O'Donoghue B; Clarke M; O'Connor K; Cannon M; Cotter DR
Brain Behav Immun; 2024 Jun; ():. PubMed ID: 38857636
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of plasma soluble urokinase plasminogen activator receptor (SuPAR) levels in ulcerative colitis.
Erbak Yılmaz H; Aksun S; Günay S; Elmalı F; Çekiç C
Arab J Gastroenterol; 2023 Aug; 24(3):175-179. PubMed ID: 37045728
[TBL] [Abstract][Full Text] [Related]
8. Periodontal Clinicoradiographic Status and Whole Saliva Soluble Urokinase Plasminogen Activation Receptor and Tumor Necrosis Factor Alpha Levels in Type-2 Diabetic and Non-diabetic Individuals.
Ali D; Qasem SS; Baskaradoss JK
Oral Health Prev Dent; 2021 Jan; 19():481-488. PubMed ID: 34585873
[TBL] [Abstract][Full Text] [Related]
9. Role of soluble urokinase plasminogen activator receptor in critically ill children with hospital-acquired pneumonia: an observational study in hospital with controls.
Saleh NY; Soliman SE; Aboukoura MA; Garib MI
BMJ Paediatr Open; 2024 Jan; 8(1):. PubMed ID: 38176706
[TBL] [Abstract][Full Text] [Related]
10. Overall and inter-individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes.
Rotbain Curovic V; Houlind MB; Kroonen MYAM; Jongs N; Zobel EH; Hansen TW; Tavenier J; Eugen-Olsen J; Laverman GD; Kooy A; Persson F; Rossing P; Heerspink HJL
Diabetes Obes Metab; 2023 Nov; 25(11):3152-3160. PubMed ID: 37417375
[TBL] [Abstract][Full Text] [Related]
11. Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease.
Goodchild TT; Li Z; Lefer DJ
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36519539
[TBL] [Abstract][Full Text] [Related]
12. Febrile Phase Soluble Urokinase Plasminogen Activator Receptor and Olfactomedin 4 as Prognostic Biomarkers for Severe Dengue in Adults.
Teo A; Le CTT; Tan T; Chia PY; Yeo TW
Clin Infect Dis; 2024 Mar; 78(3):788-796. PubMed ID: 37823481
[TBL] [Abstract][Full Text] [Related]
13. Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis.
Hindy G; Tyrrell DJ; Vasbinder A; Wei C; Presswalla F; Wang H; Blakely P; Ozel AB; Graham S; Holton GH; Dowsett J; Fahed AC; Amadi KM; Erne GK; Tekmulla A; Ismail A; Launius C; Sotoodehnia N; Pankow JS; Thørner LW; Erikstrup C; Pedersen OB; Banasik K; Brunak S; Ullum H; Eugen-Olsen J; Ostrowski SR; ; Haas ME; Nielsen JB; Lotta LA; ; Engström G; Melander O; Orho-Melander M; Zhao L; Murthy VL; Pinsky DJ; Willer CJ; Heckbert SR; Reiser J; Goldstein DR; Desch KC; Hayek SS
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36194491
[TBL] [Abstract][Full Text] [Related]
14. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Is a Biomarker Associated with Left Ventricular Hypertrophy in the Elderly, Specifically in Women.
Wlazeł RN; Guligowska A; Chrząstek Z; Kostka T; Jegier A; Szadkowska I
J Clin Med; 2023 May; 12(9):. PubMed ID: 37176730
[TBL] [Abstract][Full Text] [Related]
15. Detection of Inflammatory Biomarker suPAR in COVID-19 Disease With CHORUS TRIO Instrument.
Helena C; Giulia T; Alessandra C; Roberto G; Caterina S; Sabrina G; Simone B; Tommaso B; Alessandra B; Roberto L
Biomark Insights; 2023; 18():11772719231210407. PubMed ID: 38035182
[TBL] [Abstract][Full Text] [Related]
16. The Relationship Between Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Treatment Response in Patients With Glomerulonephritis: A Single-Center Experience.
İşsever K; Dheir H
Cureus; 2023 Oct; 15(10):e47473. PubMed ID: 38021795
[TBL] [Abstract][Full Text] [Related]
17. The Association of suPAR with Cardiovascular Risk Factors in Young and Healthy Adults.
Wohlwend NF; Grossmann K; Aeschbacher S; Weideli OC; Telser J; Risch M; Conen D; Risch L
Diagnostics (Basel); 2023 Sep; 13(18):. PubMed ID: 37761305
[TBL] [Abstract][Full Text] [Related]
18. The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer.
Blomberg K; Hansen TF; Brasen CL; Madsen JB; Jensen LH; Thomsen CB
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680247
[TBL] [Abstract][Full Text] [Related]
19. Role of Formyl Peptide Receptors and β-Arrestin-1 in suPAR Signal Transduction in Mouse Podocytes: Interactions with αVβ3-Integrin.
Kim EY; Dryer SE
Cells; 2024 Jan; 13(2):. PubMed ID: 38247863
[TBL] [Abstract][Full Text] [Related]
20. Elevated soluble urokinase plasminogen activator receptor is associated with renal dysfunction in a Chlorocebus atheiops COVID-19 model.
Gonzalez AA; Olsen EL; Killeen SZ; Blair RV; Seshan SV; Jaimes EA; Roy CJ; Prieto MC
J Med Primatol; 2023 Apr; 52(2):131-134. PubMed ID: 36377612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
